Press Releases Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
2.72 ^HKD	+0.74%		+4.21%	-27.08%

Mar. 27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	Dec. 12	PU
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	Dec. 05	AQ
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	Oct. 31	PU
Luye Pharma : The World’s Only Goserelin Microsphere Formulation (Baituowei) Approved in China for the New Indication of Breast Cancer	23-09-07	PU
Luye Pharma : Announces 2023 Half Year Results	23-08-30	PU
Luye Pharma : China’s NMPA Accepts and Grants Priority Review Designation to the New Drug Application for Luye Pharma’s Rotigotine Extended-Release ...	23-08-01	PU
Luye Pharma : Patient Enrollment Completed for a Phase 2 Clinical Study of Luye Pharma’s Class 1 Analgesic Drug Candidate LY03014	23-07-06	PU
Bone Metastases Pipeline, Clinical Trials, and Key Companies\|Companies - Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc.	23-06-13	AQ
PharmaMar and Luye Pharma announce the acceptance of the registration application for the approval of lurbinectedin in China	23-06-07	AQ
Luye Pharma : and Duopharma Reach Strategic Partnership to Expand Accessibility of Cholesterol Management Products in Malaysia	23-04-04	PU
Luye Pharma : Receives Clinical Trial Approval in Europe for Its Innovative Formulation Paliperidone Palmitate Long-acting Injection ...	23-02-23	PU
Luye Pharma : 3-month Long-acting Goserelin Microspheres Approved for Clinical Trials in China	23-01-30	PU
Luye Pharma : Innovative Anti-Cancer Therapy Lurbinectedin to Benefit “Named Patients” in Hong Kong	23-01-09	PU
Luye Pharma : Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China	23-01-09	PU
Luye Pharma : Boan Biotech Officially Listed on the Main Board of SEHK Accelerating to Become a Leading Global Biopharmaceutical Company	22-12-29	PU
Luye Pharma : World’s First Denosumab Biosimilar Boyoubei® Launched in China	22-12-09	PU
Luye Pharma : Innovative Drug Ruoxinlin® Launched in China Bringing the treatment of major depressive disorder to a new ...	22-12-05	PU
Luye Pharma : First Patient Dosed for Luye Pharma’s Investigational Analgesic LY03014 in a Phase II Clinical Study	22-11-30	PU
Luye Pharma : Innovative Formulation LY03010 Meets Endpoints in Pivotal U.S. Study	22-11-20	PU
China Approves World's First Denosumab Biosimilar	22-11-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Press Releases

Filters